Related Experiment Videos
[Allergo-immunology. 1. Eosinophiles: old knowledge... and new pathologies]
1Service d'immunologie et d'allergie, CHUV, 1011 Lausanne. Francois.Spertini@chuv.hospvd.ch
Revue Medicale Suisse
|March 19, 2005
Summary
Eosinophilic gastrointestinal diseases involve eosinophil buildup. Anti-interleukin-5 antibody therapy reduced extracellular matrix deposition in asthma patients, suggesting a role in limiting bronchial remodeling.
Area of Science:
- Gastroenterology
- Immunology
- Pulmonology
Background:
- Eosinophilic gastrointestinal diseases (EGID) affect the GI tract and are linked to atopy.
- Proximal esophageal inflammation has a better prognosis than distal eosinophilic infiltrations, which can lead to hypereosinophilic syndrome.
- Interleukin-5 (IL-5) is crucial for eosinophil recruitment to the GI tract and lungs.
Observation:
- Clinical trials investigated anti-IL-5 monoclonal antibodies (mAbs) for asthma.
- The treatment showed limited efficacy on bronchial hyperreactivity and eosinophil infiltration in the lungs.
Findings:
- Anti-IL-5 mAb therapy significantly decreased extracellular matrix deposition in asthma patients.
- This suggests a potential role for anti-IL-5 mAbs beyond direct eosinophil inhibition.
Implications:
- Targeting IL-5 may offer a strategy to limit bronchial remodeling in conditions involving eosinophilic inflammation.
- Further research is warranted to explore the therapeutic potential of anti-IL-5 mAbs in EGID and related fibrotic conditions.